Cinnamon and traumatic brain injury

肉桂和创伤性脑损伤

基本信息

  • 批准号:
    10553165
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-01 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Traumatic brain jury (TBI) and associated co-morbidities are important contributors of disability among military personnel. Therefore, it is an urgent need to find an effective, a safe and an economical solution for this. Axonal injury is an important contributor to the behavioral deficits observed following TBI. It is believed that axonal injury during TBI is potentiated by neuroinflammation and demyelination and/or failure to remyelination. Cinnamon is a commonly used flavoring material and its metabolite sodium benzoate (NaB) is a widely-used food preservative and a FDA-approved drug for the treatment of urea cycle disorders and non-ketotic hyperglycinemia in children. Here, we will examine an exciting hypothesis that cinnamon metabolite NaB binds to the ligand-binding domain of peroxisome proliferator-activated receptor beta (PPARβ) (Specific aim I) to induce anti-inflammation in microglia and promote maturation of OPCs (Specific aim II), resulting in neuroprotection in a mouse model of TBI (Specific aim III). A positive outcome of this cutting-edge merit proposal will delineate NaB as a new nontoxic ligand of PPARβ and enhance the possibility of attenuating microglial activation, promoting remyelination and treating TBI patients with cinnamon and its metabolite NaB as primary or adjunct therapy.
创伤性脑损伤(TBI)及相关合并症是导致脑损伤的重要因素

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KALIPADA PAHAN其他文献

KALIPADA PAHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KALIPADA PAHAN', 18)}}的其他基金

Remyelination by intranasal TIDM peptide
鼻内 TIDM 肽进行髓鞘再生
  • 批准号:
    10582863
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Intranasal TIDM peptide for tauopathy
用于治疗 tau 蛋白病的鼻内 TIDM 肽
  • 批准号:
    10274908
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Muscle building supplement HMB for remyelination
用于髓鞘再生的增肌补充剂 HMB
  • 批准号:
    10442389
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Intranasal TIDM peptide for tauopathy
用于治疗 tau 蛋白病的鼻内 TIDM 肽
  • 批准号:
    10059127
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Muscle building supplement HMB for remyelination
用于髓鞘再生的增肌补充剂 HMB
  • 批准号:
    10202489
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Cinnamon and traumatic brain injury
肉桂和创伤性脑损伤
  • 批准号:
    9888950
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Muscle building supplement HMB for remyelination
用于髓鞘再生的增肌补充剂 HMB
  • 批准号:
    10281373
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Muscle building supplement HMB for remyelination
用于髓鞘再生的增肌补充剂 HMB
  • 批准号:
    10654820
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Cinnamon and traumatic brain injury
肉桂和创伤性脑损伤
  • 批准号:
    10438526
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
BLR&D Research Career Scientist Application
BLR
  • 批准号:
    10047235
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了